BioCentury
ARTICLE | Clinical News

Betmiga mirabegron regulatory update

July 1, 2013 7:00 AM UTC

The U.K.'s NICE issued final guidance recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not sui...